Business Wire

OR-RADISYS

Share
Radisys Unveils Engage Clarity to Enhance Phone Conversations for People Experiencing Hearing Loss

The World Health Organization estimates that 20% of the world’s population today suffers from some degree of hearing loss. This figure is expected to increase to an estimated 25% (nearly 2.5 billion) by 2050. Over time, individuals with hearing loss tend to stop socializing – leading to impacts on friends and family members as well as increasing the risk of other health issues, including a higher likelihood of dementia. Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.

Radisys® Corporation, a global leader of open telecom solutions, today announced the availability of Engage Clarity, a unique service that enhances the quality and comprehensibility of voice calls for people with hearing challenges. With the goal to significantly enhance their quality of life and interactions, a personalized and unique service profile is activated, enabling in-line, real-time enhancements that deliver a superior experience. Engage Clarity seamlessly integrates with telecom operators' communication networks, ensuring a smooth and user-friendly implementation experience without requiring any special applications and devices. The Engage Clarity is accessible via any device through mobile voice, fixed voice, or OTT/web communication service.

With Radisys’ Engage Clarity, MNOs have a unique opportunity to offer a fully personalized wellness solution to their subscribers and meet inclusivity and societal improvement objectives. With a suggested street price per month that is less than the cost of a cup of coffee, this unique solution enhances the quality of life and improves accessibility to services for people with hearing loss. The solution benefits can be extended to anyone in consumer and business calls.

With global leadership in media processing, Radisys is uniquely positioned to deliver the benefits of Engage Clarity through service providers. “The ability to ensure the voice clarity in conversations between grandparents and grandchildren, patients and doctors, businesses and their customers – regardless of the background noise - has broad benefits to users and operators,” said Al Balasco, Head of Digital Experiences and Applications Business, Radisys. “Voice is communication’s lowest common denominator, and ensuring the highest quality experience can be life-changing for those experiencing hearing challenges.”

Radisys’ Engage Clarity addresses a critical need for people with hearing difficulties during voice calls. Clinical trials revealed high levels of user satisfaction, with 90% of users finding speech clearer and easier to hear and 74% of users reporting that calls were less tiring, highlighting the positive impact of the service on the overall communication experience for everyone, not only people with hearing difficulties.

Hearing wellness is often neglected. Compared to examining their eyes annually, people rarely take a hearing test. Radisys’ Engage Clarity offers a unique entry point for MNOs to help people manage hearing wellness by suggesting regular check-ins with the Engage hearing profile creator when they change their handset or perhaps once a year.

Experience Engage Clarity at MWC Barcelona

Hear the difference Radisys’ Engage Clarity brings. Visit Radisys at MWC Barcelona, Stand 2D50 for a demonstration, or learn more by visiting www.engagedigital.ai/clarity. To schedule a meeting with Radisys’ experts, contact open@radisys.com.

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240225545999/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye